GoodRx Holdings, Inc. - GDRX STOCK NEWS

GoodRx Holdings (Nasdaq: GDRX) announced that Scott Wagner has joined its Board of Directors as Co-Chair, effective January 21, 2025. Wagner, who served as Interim CEO from April 2023 to January 2025, will serve alongside existing Co-Chair Trevor Bezdek and chair the Board's Compensation Committee.

Wagner brings over 25 years of executive leadership experience, notably as CEO, President, COO, and CFO at GoDaddy, where he helped triple revenue to nearly $3 billion and expanded services globally. Previously, he was a Partner at KKR from 2000 to 2012, leading the Capstone team.

The appointment coincides with Simon Patterson's resignation from the board, including his positions on the Nominating and Corporate Governance Committee and Innovation Committee.

GoodRx (GDRX) has announced free online healthcare provider visits for California residents affected by the Los Angeles County wildfires. Using the code LA-GOODRX-CARE, residents can access GoodRx Care for various medical conditions and prescription refills, regardless of insurance status.

The initiative allows affected residents to consult with licensed medical professionals who can refill existing medications and send prescriptions to local pharmacies. The company is also providing guidance on accessing emergency refills through insurance companies, saving up to 80% on prescriptions using GoodRx, and transferring prescriptions to different pharmacies if needed.

As a Santa Monica-based company, GoodRx aims to ensure community members can maintain access to essential medications and healthcare during the wildfire crisis, particularly for those who may have lost or left behind medications during evacuation.

GoodRx (GDRX) has launched 'GoodRx for Pets,' a new platform offering savings and home delivery for pet medications. The service aims to address the rising cost of pet healthcare, which saw Americans spend over $13 billion on pet medications in 2023. With pet care prices increasing 25% in the last five years and only 3% of pets having insurance coverage, the platform offers up to 80% savings on medications at over 70,000 retail pharmacies nationwide.

The new service, powered by Allivet, includes an integrated e-commerce experience for direct-to-door delivery and access to pet-specific medications not available in retail pharmacies. The platform also provides expert-created educational content on pet health. GoodRx reports that pet owners have already been using their platform for millions of prescriptions annually, prompting this dedicated pet-focused expansion.

WM Technology (Nasdaq: MAPS) has appointed Sarah Griffis as its new Chief Technology Officer, effective January 6, 2025. Griffis brings experience from regulated industries, having previously served as CTO at Cerebral, a digital healthcare company, and held engineering leadership positions at GoodRx and Kindbody.

CEO Doug Francis expressed enthusiasm about Griffis joining the cannabis marketplace and technology solutions provider, highlighting her experience in building engineering teams and operating in regulated industries. Griffis, a Caltech graduate in Environmental Science Engineering, stated her commitment to improving the company's product and creating greater efficiencies for customers and clients.

GoodRx Holdings (Nasdaq: GDRX), the leading prescription savings platform in the U.S., has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. Company executives will engage in a fireside chat on Wednesday, January 15, 2025 at 9:45 a.m. Pacific Time (12:45 p.m. Eastern Time).

The event will be accessible via live webcast on GoodRx's Investor Relations website. An archived recording of the presentation will remain available on the company's website for a minimum of 30 days following the conference.

GoodRx (GDRX) has released a critical healthcare report revealing that nearly 70% of U.S. counties lack endocrinologists, affecting approximately 50 million Americans. The study shows people in these 'endocrinology deserts' face a 12% higher mortality rate from endocrine-related diseases.

The shortage particularly impacts diabetes care, with death rates more than doubling in affected areas. For example, Buffalo County, South Dakota reports 143.3 deaths per 100,000 compared to 56.6 in Bell County, Kentucky, where specialists are available.

To address these challenges, GoodRx offers up to 80% savings on diabetes medications, with 20 medications under $20, exclusive brand-name discounts on GLP-1 and GIP medications, and comprehensive healthcare resources through their Diabetes Center.

GoodRx Holdings (NASDAQ: GDRX) has appointed Wendy Barnes as President and Chief Executive Officer, effective January 1, 2025. Barnes brings over 30 years of healthcare leadership experience, joining from RxBenefits where she served as CEO, managing pharmacy benefit support for more than 2,000 self-insured clients with over three million lives. Previously, she was President of Express Scripts Pharmacy and Group Vice President at Rite Aid.

In her new role, Barnes will focus on advancing GoodRx's strategic initiatives, including expanding brand affordability programs, enhancing product experience with healthcare professionals, and strengthening partnerships with retail pharmacies, insurers, and pharmaceutical manufacturers. She succeeds Scott Wagner, who served as Interim CEO.

GoodRx has released a new Weight Loss Medications Tracker revealing significant trends in medication usage and spending. Despite insurance coverage and high costs, fill rates for weight loss drugs have surged dramatically in 2024, with Wegovy increasing by 100% and Zepbound by 300%. The research shows Americans overspent by $200 million in 2024 by paying full retail prices instead of using available savings.

Insurance coverage remains , with only 9% of people having unrestricted coverage for Zepbound and 14% for Wegovy. Even with insurance, patients face high out-of-pocket costs, averaging over $2,500 annually for Zepbound. Regional disparities show Alaska leading in overall fill rates, while Massachusetts, New Jersey, Rhode Island, and Delaware show higher rates for specific weight loss medications.

Harrow (HROW) announced a new initiative to improve access and affordability of its ophthalmic pharmaceutical products through two main strategies. First, the company is implementing price reductions for several products, starting with VIGAMOX® and MAXIDEX®. Second, Harrow established a partnership with GoodRx to provide discounted pricing for seven products including FLAREX®, ILEVRO®, MAXIDEX®, TOBRADEX® ST, VEVYE®, VIGAMOX®, and ZERVIATE® through GoodRx's platform, particularly benefiting uninsured and underinsured patients.